Match Document Document Title
8710004 Stable liquid VEGF antagonist formulations  
Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a...
8709434 Compositions for inhibiting NADPH oxidase activity  
Phycobilins are disclosed to have prodrug activity as inhibitors of NADPH oxidase activity and are disclosed to be useful in the prophylaxis and/or treatment of medical conditions associated with...
8709446 HYR1 as a target for active and passive immunization against Candida  
The invention features HYR1 as a vaccine target and as a prophylactic strategy for combating disseminated candidiasis.
8709435 Hypallergenic mosaic antigens and methods of making same  
Hypoallergenic mosaic antigens assembled from naturally-occurring allergens are disclosed herein. Also disclosed are methods of making such hypoallergenic mosaic antigens, particularly those...
8703908 Expression and export of angiogenesis inhibitors as immunofusins  
A fusion protein of the invention comprises an immunoglobulin Fc region and a first target protein linked to the immunoglobulin Fc region. The first target protein comprises a collagen XVIII...
8703432 Recombinant Treponema spp. proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same  
The present invention relates to proteins and/or fragments and derivatives thereof and their use as vaccines and in biotechnological methods. The vaccines particularly include immunogenic proteins...
8703144 Allergen peptide fragments and use thereof for treatment of dust mite allergies  
The present invention relates generally to in vivo methods and compositions designed for allergen specific immunotherapy. The compositions include contiguous overlapping peptide fragments which...
8703151 Tuberculosis vaccines comprising antigens expressed during the latent infection phase  
The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M....
8703148 Immunogenic composition  
The present application relates to immunogenic compositions comprising staphylococcal PNAG which is less than 40% N-acetylated and is conjugated to a carrier protein by a linker bonded to an amine...
8703702 Therapeutically active α-MSH analogues  
The invention describes peptide analogues of α-melanocyte-stimulating hormone (α-MSH), which possess an increased efficacy compared to the native α-MSH peptide. The α-MSH analogues exhibit...
8703147 Methods and compositions for treating and preventing malaria (2)  
The present invention provides compositions and methods useful in the treatment or prevention of a condition caused by or associated with infection by Plasmodium falciparum, such as malaria. The...
8703705 Modified factor VIII peptides  
The present invention provides peptides at least partly derivable from FVIII which are capable of binding to an MHC class II molecule without further antigen processing and being recognized by a...
8697082 Prevention and treatment of synucleinopathic and amyloidogenic disease  
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such...
8697081 Method of modulating neovascularization  
The invention provides a method of inhibiting neovascularization in a subject. The method comprises administering to the subject an agent that interferes with fibronectin (Fn) matrix assembly in...
8697076 Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies  
Antibodies selective for pathological tau dimers and/or prefibrillar pathological tau oligomers, immunogenic peptides and epitopes of these antibodies, hydridomas producing these antibodies, uses...
8697083 Hypoallergenic chimeric proteins belonging to the lipid transfer family of parietaria judaica for use in the treatment of allergies  
The present invention relates to recombinant DNA molecules which encode chimeric polypeptides of differing allergens of Parietaria judaica which can be used for the prevention and treatment of...
8697091 Mycobacterium antigens  
There is provided a diagnostic reagent for use in the detection of M. bovis or M. tuberculosis infection in an animal, comprising a peptide which has an epitope from Mycobacterium bovis hypothetic...
8691236 Vaccine for a therapeutic or a prophylactic treatment of myasthenia gravis  
Complementary peptide having at least a sequence complementary to a major immunogenic region of an acetylcholine receptor involved in myasthenia gravis, characterized in that the complementary...
8691945 Antimicrobial peptides  
There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3...
8691237 Brucella abortus proteins and methods of use thereof  
Compositions and methods for the diagnosis and prevention of B. abortus infection are provided.
8685404 Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction  
Methods are provided for the treatment of subjects with cognitive or neuropsychiatric impairment induced by substance addiction and for increasing cognitive function in a subject with substance...
8685403 Insulin-like growth factor signaling and integrin  
Interaction between insulin-like growth factor 1 (IGFI) and integrin is involved in integrin-mediated cellular signaling, such as enhanced proliferation of cells expressing integrins, especially...
8673293 Use of modified cells for the treatment of multiple sclerosis  
The present invention describes blood cells chemically coupled with immunodominant myelin peptides and their use in the treatment of Multiple Sclerosis.
8673319 Chimpanzee adenovirus vaccine carriers  
The present invention provides recombinant replication-defective adenoviral vectors derived from chimpanzee adenoviruses and methods for generating recombinant adenoviruses in human E1-expressing...
8669355 Vaccine  
The present invention is concerned with the development of a vaccine against Aeromonas hydrophila for use especially in fish. The invention provides an immunogenic S-layer protein of approximately...
8663645 Use of native peptides and their optimized derivatives for vaccination  
The present invention pertains to the field of vaccination, and more particularly to the fields of antitumor and antiviral vaccination. The invention relates to the use of a native peptide in a...
8663651 T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation  
The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for...
8663646 P53 peptide vaccine  
The invention relates to a peptide derived from p53 that could be used as a vaccine against cancer.
8663647 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides  
The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2,...
8658177 Promiscuous HER-2/Neu CD4 T cell epitopes  
The present invention relates to the discovery of novel T cell epitopes of the human HER-2/Neu protein that is promiscuous for at least 25 different HLA-DR alleles. The invention also relates to...
8658766 Soluble hybrid Fcγ receptors and related methods  
Disclosed are soluble hybrid Fcγ receptor (FcγR) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also...
8658176 Lipidated tumor-associated antigens and immunotherapeutic compositions  
Disclosed are polypeptides and fusion proteins. Also disclosed are related immunotherapeutic compositions and methods.
8658180 Vaccines against influenza virus  
Disclosed are immunogenic conjugates having the general formula: M2e-Cys-S—CH2—C(O)—NH—CH2—CH2-C(O—)NH-Lys-Pr, were M2e is the influenza M2 ectodomain (M2e) peptide; Cys is a cysteine amino acid...
8652485 Peptide for vaccine  
The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or...
8652488 Insulin B chain autoantigen composition  
The invention features methods for the prevention or treatment of autoimmune disorders in humans. The methods include administering an autoantigen in combination with an oil-based carrier....
8652484 Delivery system for cytotoxic drugs by bispecific antibody pretargeting  
The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a...
8647634 Recombinant avian infectious coryza vaccine and process for preparing same  
A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of...
8647629 Powerful MHC-class II peptides derived from survivin  
The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic...
8647630 Mite allergen  
A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following...
8647628 Peptide epitopes of apolipoprotein B  
The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including...
8647631 Pharmaceutical composition of an antigenic tau peptide reconstituted in a liposome and related antibodies and cell lines  
The present invention is related to methods and pharmaceutical compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with...
8647818 Molecular scaffolds for HIV-1 immunogens  
Methods and compositions are provided which employ chimeric polypeptides having at least one heterologous epitope for a human immunodeficiency virus type 1 (HIV-1) neutralizing antibody. These...
8647632 Proteins  
Provided herein are four polypeptides, named PRT5, PRT6, PRT7 and PRT8, the nucleic acids encoding the same, compositions comprising the proteins, as well as their uses in therapeutic and...
8642043 Peptide epitopes of apolipoprotein B  
The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including...
8642044 Prevention and treatment of amyloidogenic disease  
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce...
8637013 Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis  
The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24...
8637040 Genus-wide chlamydial peptide vaccine antigens  
Peptides generated from a random library that are bound by a monoclonal antibody to Chlamydial glycolipid exoantigen (GLXA) and thus mimic this antigen are disclosed. Peptides that correspond to...
8637041 Secreted Campylobacter flaggella coregulated proteins as immunogens  
The invention relates to an immunogenic composition composed of secreted polypeptides derived from Campylobacter jejuni non-flagellar proteins that are coordinately expressed with the flagellar...
8637028 Adjuvant incorporation in immunonanotherapeutics  
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in...
8637053 Chlamydia antigens  
Chlamydia antigens (e.g., polypeptides, polypeptide fragments, and fusion proteins) are provided. Also provided are vaccines and pharmaceutical compositions for treating or preventing a bacterial...